Table 2.
Subgroup analysis of morpho-structural and functional cardiac parameters at cardiac magnetic resonance according to disease status
| Controls (n = 17) |
Active a (n = 14) |
Cured b (n = 6) |
Pc value | Pd value | Pe value | |
|---|---|---|---|---|---|---|
| Sex (M/F) | 8/9 | 10/4 | 3/3 | 0.461 | 1.000 | 0.202 |
| Age, years | 57 ± 11 | 50 ± 14 | 49 ± 8 | 0.232 | 0.335 | 0.986 |
| Years from diagnosis | NA | 8 (2.0-24.8) | 10 (1.7–31.7) | - | - | 0.552 |
| Time until disease control (months) | NA | 48.5 (7.0-216.0) | 56.0 (5.0-148.0) | - | - | 0.754 |
| GH at diagnosis | NA | 16.3 ± 12.7 | 17.9 ± 12.6 | - | - | 0.509 |
| IGF1 xULN at diagnosis | NA | 2.66 [1.34–5.92] | 1.69 [0.82–2.03] | - | - | 0.076 |
| IGF1 xULN at baseline | NA | 0.80 (0.54–1.16) | 0.62 (0.34–0.74) | - | - | 0.130 |
| LV-EDVi (ml/m2) | 61.7 ± 11.5 | 82.0 ± 14.9* | 74.3 ± 9.8 | < 0.001 | 0.110 | 0.438 |
| LV-ESVi (ml/m2) | 23.8 ± 7.0 | 35.6 ± 7.4* | 29.8 ± 8.0 | < 0.001 | 0.206 | 0.252 |
| LV-SVi (ml/m2) | 37.9 ± 7.1 | 46.3 ± 10.5§ | 44.4 ± 5.2 | 0.023 | 0.243 | 0.889 |
| LV-EF (%) | 61.5 ± 6.7 | 56.4 ± 5.9 | 60.1 ± 6.3 | 0.083 | 0.894 | 0.462 |
| LVMi (g/m2) | 43.5 ± 8.5 | 62.0 ± 12.1* | 45.5 ± 12.5# | < 0.001 | 0.915 | 0.009 |
| Concentricity index (g/mL) | 0.73 ± 0.19 | 0.76 ± 0.11 | 0.62 ± 0.20 | 0.905 | 0.343 | 0.222 |
| RV-EDVi (ml/m2) | 63.4 ± 9.7 | 90.8 ± 21.5* | 87.1 ± 16.1§ | < 0.001 | 0.012 | 0.887 |
| RV-ESVi (ml/m2) | 25.8 ± 6.4 | 45.5 ± 12.6* | 43.1 ± 15.0 | < 0.001 | 0.005 | 0.894 |
| RV-SVi(ml/m2) | 37.9 ± 7.6 | 45.3 ± 10.8 | 44.0 ± 4.8 | 0.069 | 0.329 | 0.949 |
| RV-EF (%) | 59.3 ± 7.7 | 50.2 ± 5.3* | 51.4 ± 7.9 | 0.003 | 0.058 | 0.931 |
| T1-preMean (ms) | 997.1 ± 18.7 | 991.8 ± 33.8 | 1005 ± 21.5 | 0.899 | 0.844 | 0.610 |
| T1-postMean (ms) | 408.8 ± 42.9 | 446.9 ± 54.1 | 446.6 ± 63.9 | 0.106 | 0.317 | 1.000 |
| ECV (%) | 25.9 ± 2.1 | 26.1 ± 2.6 | 25.6 ± 3.4 | 0.981 | 0.966 | 0.922 |
Morpho-structural and functional cardiac parameters in matched controls and patients with acromegaly, after stratification according to disease status
a Patients were defined as “active” in case of persistently elevated IGF1 levels, thus requiring medical treatment for acromegaly
b Patients were defined as “cured” in case of persistent biochemical remission [i.e., nadir GH levels < 0.4 µg/L during oral glucose tolerance test, IGF1 per upper limit of normal (ULN) < 1] following pituitary adenomectomy
c Healthy controls vs. patients with active acromegaly
d Healthy controls vs. patients cured from acromegaly
e Hatients cured from acromegaly vs. patients with active acromegaly
M = male, F = female, NA = not applicable, LV-EDVi = left ventricle end-diastolic volume indexed, LV-ESVi = left ventricle end-systolic volume indexed, LV-SVi = left ventricle stroke volume indexed, LV-EF = left ventricle ejection fraction, LVMi = left ventricle mass indexed, IVS = interventricular septum, RV-EDVi = right ventricle end-diastolic volume indexed, RV-ESVi = right ventricle end-systolic volume indexed, RV-SVi = right ventricle stroke volume indexed, RV-EF = right ventricle ejection fraction, ECV = extracellular volume